

Product datasheet for TR318731

VAMP2 Human shRNA Plasmid Kit (Locus ID 6844)

Product data:

| | |
|---------------------------|---|
| Product Type: | shRNA Plasmids |
| Product Name: | VAMP2 Human shRNA Plasmid Kit (Locus ID 6844) |
| Locus ID: | 6844 |
| Synonyms: | NEDHAHM; SYB2; VAMP-2 |
| Vector: | pRS (TR20003) |
| E. coli Selection: | Ampicillin |
| Mammalian Cell Selection: | Puromycin |
| Format: | Retroviral plasmids |
| Components: | VAMP2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 6844). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
| RefSeq: | NM_014232 , NM_001330125 , NM_014232.1 , NM_014232.2 , BC033870 , BC033870.1 , BC002737 , BC019608 , NM_014232.3 |
| UniProt ID: | P63027 |
| Summary: | The protein encoded by this gene is a member of the vesicle-associated membrane protein (VAMP)/synaptobrevin family. Synaptobrevins/VAMPs, syntaxins, and the 25-kD synaptosomal-associated protein SNAP25 are the main components of a protein complex involved in the docking and/or fusion of synaptic vesicles with the presynaptic membrane. This gene is thought to participate in neurotransmitter release at a step between docking and fusion. The protein forms a stable complex with syntaxin, synaptosomal-associated protein, 25 kD, and synaptotagmin. It also forms a distinct complex with synaptophysin. It is a likely candidate gene for familial infantile myasthenia (FIMG) because of its map location and because it encodes a synaptic vesicle protein of the type that has been implicated in the pathogenesis of FIMG. [provided by RefSeq, Jul 2008] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).